

 IVA Company News

Viva Biotech Announced the Establishment of AI New Drug Incubation Center in Jiaxing

On November 18, 2021, Viva Biotech signed a strategic cooperation agreement with Xiuzhou District People's Government of Jiaxing Municipal to announce the establishment of Viva Biotech's AI New Drug Incubation Center in Xiuzhou District. The two parties will jointly establish an advanced cryoEM and a supercomputing center.



Six from the left: Dr. Chen Mao, Chairman and CEO of Viva Biotech

Viva BioInnovator (VBI) Successfully Held the 4th Demo Day



On October 29, 2021, the 4th Viva BioInnovator (VBI) Demo Day was successfully held online. The Demo Day selected six biomedical start-ups incubated by VBI for the roadshow. Nearly 200 domestic and overseas top-tier investors, representatives of investment institutions, R&D representatives of pharmaceutical companies, etc., participated and conducted in-depth communication with company founders in an interactive way online.

Viva Biotech and NanoImaging Services will collaborate based on cryoEM technology

On October 13, 2021, Viva Biotech has reached a strategic cooperation agreement with NanoImaging Services that will provide clients with integrated services from gene to structure analysis based on cryoEM technology.



Langhua Pharmaceutical announced the appointment of Dr. Mingda Bi as Vice President



On August 13, 2021, Langhua Pharmaceutical, a non-wholly owned subsidiary of Viva Biotech, announced the appointment of Dr. Mingda Bi as Vice President, who will be responsible for the Formulation Department and report directly to Dr. Jianguo Ma, CEO of Langhua Pharmaceutical.

Viva BioInnovator was Listed as the First Batch of GOIs

On July 29, 2021, the “Group Open Innovation Center Plan” (“GOI”), organized by the People’s Government of Shanghai Pudong New Area, was officially launched in Shanghai Science and Technology Museum. Viva Biotech was invited to attend the ceremony and listed as the first batch of GOIs.



ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310.

On November 30, 2021, ABM Therapeutics (ABM), a biomedical innovation company, announced that its IND application for ABM-1310, a new-generation BRAF inhibitor has been approved by the National Medical Products Administration (NMPA) to conduct Phase 1 clinical trials in patients of advanced solid tumors with BRAF mutation in China. This is the first clinical candidate and IND approval obtained by ABM Therapeutics in China.



ABM Therapeutics and Sansheng Pharmaceuticals Announced a Strategic Cooperation.

On August 31, 2021, ABM Therapeutics, a biomedical innovation company, focusing on the research and development of small-molecule targeted drugs that can break through the blood-brain barrier, and Sansheng Pharmaceuticals, the pioneer of antibody drugs in China, jointly announced a strategic cooperation agreement. The two parties will conduct extensive cooperation on the clinical development and registration of innovative anti-tumor drug combinations for the Chinese market.

Eubulus Biotherapeutics Cooperate with Coherent Biopharma to develop Targeted Protein Degradation.

Recently, Eubulus Biotherapeutics announced a strategic collaboration with Coherent Biopharma. Eubulus Biotherapeutics has licensed out its dual-targeted protein degradation molecule developed on the TED platform to Coherent Biopharma for global patenting, clinical development and commercialization of various solid tumor indications on the C-PROTAC technology platform.



Eubulus Biotherapeutics Completed Series A Funding of USD\$10 Million.

On October 14, 2021, Eubulus Biotherapeutics announced the closing of its USD\$10 million Series A financing. The financing was led by DaiDai Capital and Changrong Capital, and co-invested by Star Capital and other institutions. The funding will help accelerate the first bifunctional degradation agent to reach the clinical stage, aiming to fill the gap in oncology treatment as soon as possible.



Deka Biosciences Completed Series A Funding of USD\$20 Million.

On November 16, 2021, Biotech company Deka Biosciences announced the closing of its USD\$20 million Series A financing. This round was led by Leaps by Bayer and Lumira Ventures. Additional investors include O-Bio (Echo Investment Capital), Viva BioInnovator, and Alexandria Venture Investments.



Fuse Biotherapeutics was Oversubscribed in Seed Financing.

On November 15, 2021, Fuse Biotherapeutics, a company focused on developing next generation immune modulating therapeutics that directs and potentiates both innate and adaptive immunity, announced it has secured an oversubscribed and upsized \$9.5 million Seed round. The round was led by Viva Biotech. Also participating were Sherpa Healthcare Partners, Ivy Venture Group, Sirona Capital, and GC&H Investments. Proceeds from this financing will support the development of Fuse Biotherapeutics' proprietary platform.



CDE Approved IND application of Genhouse for its SHP2 inhibitor

GH21. On November 11, 2021, Genhouse Bio, a biotech company focusing on development of next-generation small molecule anti-cancer therapeutics, announced today that the Center for Drug Evaluation (CDE) has recently approved IND application for Class I new drug GH21. In addition, the U.S. IND application for GH21 has also been approved by FDA in October.

Genhouse Bio Announced First Patient First Dose Achieved in Phase I Clinical Trial of GH35.

On September 28, 2021, Genhouse Bio announced that the first patient has completed first dose in phase I clinical trial of GH35 in China. This is a multi-center, open-label phase I clinical trial to evaluate the safety, tolerability and PK profile of GH35 in patients with KRAS mutated late stage solid tumors. And this is the first-in-human clinical trial of Genhouse Bio in China.



Anji Pharma Completed the enrollment of the participants of the bridging trial in China.

On October 29, 2021, Anji Pharma announced that ANJ900 (delayed-release metformin), an innovative therapy for patients with Type 2 diabetes (T2D) including those with varying stages of renal disease, has completed the enrollment of all the participants of the bridging trial in China.

Anji Pharma Completed Series B Financing of USD\$70 Million. On September 28, 2021, Anji Pharma, an emerging global medicines company, announced the closing of a USD\$70 million Series B financing to continue global trials of its two late-stage clinical programs in metabolic disorders and to incubate multiple newly launched cancer pipeline programs. This round of funding was exclusively invested by CR Capital.



Anji Pharma's ANJ900 was Approved to Launch Key Phase III Clinical Trials in China. On July 1, 2021, Anji Pharma announced that ANJ900 (delayed-release metformin), an innovative therapy for patients with Type 2 diabetes (T2D) including those with varying stages of renal disease, has been approved by the China National Drug Administration's Drug Evaluation Center (CDE) recently, to carry out bridge tests and key clinical trials.

Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting. On October 27, 2021, Cybrexa Therapeutics invested and incubated by Viva Biotech announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex™-exatecan). The initial data show robust efficacy signals and tolerability in patients with metastatic cancer.



AR882 of Arthrosi Therapeutics was Approved to Launch Drug Clinical Trial in China. On October 20, 2021, Arthrosi announced that AR882 capsule has been granted an approval for drug clinical trial from the National Medical Products Administration of the People's Republic of China. AR882 is a globally competitive new uric acid lowering drug and a new generation of uric acid excretion promoters to treat hyperuricemia and gout.



Arthrosi Therapeutics Received USD\$25 Million Funding from ApicHope Pharmaceutical. On July 28, 2021, Arthrosi Therapeutics, Inc. announced Ruiteng Biologics (Hong Kong) Limited Company, a subsidiary of ApicHope Pharmaceutical, will participate in its Series C2 preferred shares financing with its own funds capital of USD\$25 million. Meanwhile, Arthrosi Therapeutics, Inc. announced that it would establish a joint venture with ApicHope Pharmaceutical. The joint venture will be responsible for completing the R&D of AR882 and AR035 developed by Arthrosi in China, obtaining marketing approval, and production and sales in China.



Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia. On October 19, 2021, Iterion Therapeutics, Inc., a clinical-stage biotechnology company developing novel cancer therapeutics, announced the initiation of a Phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML).



VivaVision Signed a Contract with Lin-Gang Special Area. On October 13, 2021, Dr. Wang Shen, Chairman and CEO of VivaVision, a company invested and incubated by Viva Biotech, attended the Lin-Gang Special Area Sub Forum & Biopharma Group Signing Ceremony in the International Biopharma Industry Week Shanghai 2021. The contracted projects will be used to expand R&D and promote industrialization.



IpiNovyx Bio Completed USD\$10 Million Seed Financing to Advance Immunoproteasome Inhibitors Toward. On October 11, 2021, IpiNovyx Bio, a biopharmaceutical company, announced the closing of a USD\$10 million seed financing round. The financing was led by Viva Biotech, and co-invested by Eli Lilly, Opaley Management, Orange Grove Bio and Alexandria Venture Investments. This round of financing will be used to support IpiNovyx Bio's main candidate medicine entering into first-in-human clinical trials, including submission of the company's first investigational new drug (IND) application.



Triumvira Completed First Patient Dose with Novel T Cell Therapy in TACTIC-2 Clinical Trial. On September 20, 2021, Triumvira Immunologics announced that the first patient has been dosed with novel T-cell therapy in a clinical trial called TACTIC-2. TAC technology is a potential alternative therapy to CAR-T and TCR-T.



QureBio and Hengrui Pharmaceuticals Reached a Strategic Cooperation. On September 17, 2021, QureBio, a biotech company that dedicated to the development of innovative macromolecular biological drugs, entered into a strategic cooperation agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. For the clinical treatment of advanced gastric cancer, the two parties will carry out a clinical trial of the combination therapy of Qure's Q-1802 (claudin 18.2/PD-L1 double-antibody) and Hengrui Medicine's Apatinib.



Simon Sturge Joins Mediar Therapeutics as Executive Chairman. On September 15, 2021, Mediar Therapeutics announced Simon Sturge has joined the firm as executive chairman. He will drive the development of a novel platform technology focused on the myofibroblast.



AbSci was Successfully Listed on NASDAQ after Acquiring Totient , a Viva Biotech Portfolio Company. AbSci (NASDAQ: ABSI), a synthetic biology company, was successfully listed on NASDAQ on July 22, 2021. AbSci acquired Totient, a company incubated by Viva Biotech, in June this year.

IVA About Viva Biotech

Listing Date

2019.05.09

Price (2021.12.20)

HKD 4.79

52 WK Range

HKD 4.52 - 11.64

Market Cap (2021.12.20)

HKD 9.22B

Viva Biotech's mission is to become a cradle for innovative biotechnology companies from around the world. We have developed a scalable business model combining conventional cash-for-service (CFS) CRO work and a unique investment unit with a combination of equity-for-service (EFS) and traditional cash investment. Under the CFS model, Viva provides a one-stop service for novel drug discovery and manufacturing to global pharmaceutical clients. The investment unit is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. As of June 30, 2021, Viva Biotech has provided drug discovery and production services to 1,695 pharmaceutical clients worldwide, and incubated/invested 75 biotech companies.

Viva Biotech has already completed a substantial acquisition of Langhua Pharmaceutical, a CDMO, and SYNthesis, a chemistry CRO company. We will continue building a one-stop service platform for novel drug discovery and manufacturing and assisting global biotech innovators to pursue the "0" to "1" transformation. For more information, please visit www.vivabiotech.com.

■ Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com.cn

For further information, please contact: Tel: 852-3150 6788

Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com